NCT04587011Unknown1 期
A Phase 1 Clinical Trial to Explore Pharmacokinetics, Pharmacodynamics and Safety After Twice-daily Dosing of Tegoprazan Tablets in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Pharmacokinetics Evaluation
研究概览
简要总结
The main purpose of this study is to explore the pharmacokinetics, pharmacodynamics and safety after twice-daily dosing of tegoprazan tablets in healthy subjects.
详细描述
- To explore the pharmacokinetics, pharmacodynamics and safety in accordance with the dose escalation when tegoprazan is given orally twice daily for 3 days in healthy subjects.
- To compare the pharmacodynamics and safety of tegoprazan oral administration and esomeprazole infusion for 24 hours
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 19 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects aged 19 to 45(inclusive) years at screening.
- •Subjects with body mass index (BMI) in the range of 18.5 kg/m^2 to 28.0 kg/m^2(inclusive)
- •Subjects who voluntarily agreed to participate in the study after being fully informed of the purpose, content, and characteristics of the investigational product(IP) prior to the study participation.
排除标准
- •Past medical history
- •Subjects who are determined by the investigator to have clinically significant history or disease related to the liver, kidney, digestive system, respiratory system, musculoskeletal system, endocrine system, neuropsychiatric system, hemato-oncology system, urinary system and cardiovascular system including cardiac arrhythmia.
- •Subjects who are determined by the investigator to have past history of gastrointestinal diseases (ex.: gastritis, GERD, Crohn's disease, ulcers etc.) or abdominal surgery (except simple appendectomy or herniotomy) that may affect the IP absorption.
- •Diagnostic test and electrocardiogram (ECG)
- •If H. pylori test result is positive at screening
- •If the AST or ALT value is more than 1.25 times the upper limit of normal under the screening test
- •If the total bilirubin value is more than 1.5 times the upper limit of normal under the screening test
- •If the eGFR calculated by CKD-EPI formula is less than 80 mL/min at screening
- •Subjects showing clinically significant abnormalities on ECG at screening
- •Allergy and drug abuse
- •Subjects who are hypersensitive to the investigational product or its active ingredient and any other medications (aspirin, antibiotics etc.)
- •Subjects with history of substance abuse or positive results from drug screening test.
- •Contraindicated drugs/foods
- •Subjects who have been taking any medications (including herbal medicines) or on an abnormal diet (ex: consuming more than 1L of grapefruit juice per day, large amounts of garlic, broccoli and kale, etc.) that can affect the absorption, distribution, metabolism and excretion of the IP within 28 days from the first IP administration date
- •Subjects who took any prescription drugs(ETC) or any over-the-counter drugs(OTC) within 10 days from the first IP administration date
- •Subjects who participated in other clinical trials or bioequivalence test and received other investigational product within 6 months from the first day of the IP administration (allowed to participate only if the other investigational product(s) was(were) not taken)
- •Blood donation and transfusion
- •Subjects who donated whole blood within 60 days from the first day of the investigational product administration
- •Subjects who received blood transfusion or made apheresis blood donation within 30 days from the first day of the IP administration
- •Pregnancy, Breastfeeding, and Contraception
- •Women who are pregnant, breast-feeding or have positive result on pregnancy test.
- •Subjects who are unable to use medically proven dual contraceptive methods or medically acceptable contraceptive method (intrauterine device with proven pregnancy failure rate, concurrent use of physical barrier method and spermicide, vasectomy, tubectomy/ligation, and hysterectomy, etc.) by the subject or spouse or partner from the screening date to 30 days after the last IP administration date.
- •Subjects whose weekly alcohol intake exceeds 30g/day in the last 4 weeks prior to the screening visit or found positive on alcohol test
- •Subjects who smoke more than 10 cigarettes/day per week over the last 4 weeks prior to the screening visit
- •Subjects with caffeine consumption of more than 400mg/day per week over the last 4 weeks prior to the screening visit
- •Subjects with clinically significant findings that the investigator determined to be unqualified for participation in the clinical trial
研究组 & 干预措施
T2
Experimental
Tegoprazan B mg or placebo
干预措施: Tegoprazan dose B or placebo (Drug)
T1
Experimental
Tegoprazan A mg or placebo
干预措施: Tegoprazan dose A or placebo (Drug)
T3
Experimental
Tegoprazan C mg or placebo
干预措施: Tegoprazan dose C or placebo (Drug)
T4
Experimental
Tegoprazan D mg or placebo
干预措施: Tegoprazan dose D or placebo (Drug)
结局指标
主要结局
Pharmacokinetics Evaluation
时间窗: Up to 24 hours
Vdss/F of Tegoprazan
Pharmacokinetic Evaluation
时间窗: Up to 24 hours
Css,avg of Tegoprazan and M1
次要结局
- Pharmacodynamics Evaluation(24 hours)
研究者
研究点 (1)
Loading locations...
相似试验
Enrolling By Invitation
1 期
PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy SubjectsHealthyNCT06332638HK inno.N Corporation36
已完成
1 期
Safety, PK, and PD Study of a Vaginal Insert Containing TAF and EVGHivHSVNCT03762772CONRAD16
已完成
1 期
Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy SubjectsIschemic StrokeAcute Coronary SyndromeNCT06584812Tianjin Institute of Pharmaceutical Research Co., Ltd14
招募中
1 期
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)Chronic Myeloid Leukemia, Chronic PhaseChronic Myeloid LeukemiaNCT06163430Terns, Inc.180
终止
1 期
A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell TumorSolid TumorsTenosynovial Giant Cell TumorSynovitis, Pigmented VillonodularNCT02673736Plexxikon11